University of Colorado Anschutz Medical Campus

ATLAS – Airway, Trauma, Lung injury, and Sepsis Research

We focus on epidemiological and clinical trials in the acute care setting, with a particular focus on early care of critically ill and injured patients. Our recent work incudes sepsis, respiratory failure, oxygenation strategies, and COVID-19. Our recent collaborations include the PETAL, SIREN, and IVY research networks. Our active projects are funded by NIH, DoD, and CDC.

Funded Research

Colorado PETAL Clinical Center
Funding Agency	National Heart, Lung, and Blood Institute (NHLBI)
Role	Principal Investigator (MPI)
Description / Aims	The goal of this application is to participate in the selection and conduct of clinical trials for the prevention and early treatment of acute lung injury across a network of 12 clinical centers. Our clinical center includes two academic and four community hospitals in the greater Denver area and a robust infrastructure for recruitment of critically ill emergency department and intensive care unit patients into clinical trials.
Award Number	1U01HL123010 (Ginde/Moss)
Funding Period	06/17/14-04/30/23
Amount	$373,520
Time Commitment	12.5%
Agency Contact	Lora Reineck, 301-435-0222, lora.reineck@nih.gov
Overlap	None

National Center for Advancing Translational Sciences (NCATS)
Funding Agency	Colorado Clinical and Translational Sciences Institute
Role	Co-Investigator
Description / Aims	The CTSA to the University of Colorado Denver supports the institutional academic home for research and training in clinical and translational sciences.
Award Number	UL1TR002535 (Sokol)
Funding Period	05/18/18-04/30/23
Amount	$7,927,217
Time Commitment	10%
Agency Contact	Pablo Cure, 301-827-2014,pablo.cure@nih.gov
Overlap	None

Prevention and Early Treatment of Acute Lung Injury (PETAL) Network: “Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS)
Funding Agency	National Heart, Lung, and Blood Institute (NHLBI)
Role	Co-Investigator / Site PI
Description / Aims	The goal of this phase III trial is to determine the impact of a restrictive fluids strategy (vasopressors first followed by rescue fluids) or a liberal fluid strategy (fluids first followed by rescue vasopressors) on 90-day in-hospital mortality in patients with sepsis-induced hypotension.
Award Number	U01HL123009 (Thompson/Schoenfeld)
Funding Period	06/17/2014-04/30/21
Amount	$293,207
Time Commitment	1%
Agency Contact	Lora Reineck, 301-435-0222, lora.reineck@nih.gov
Overlap	None

Brain Oxygen Optimization in Severe Traumatic Brain Injury – Phase 3 (BOOST-3)
Funding Agency	National Institute of Neurological Diseases and Stroke (NINDS)
Role	Site PI
Description / Aims	The goal of this study to determine if there is evidence of clinical efficacy of a treatment protocol based on brain tissue oxygenation (PbtO2) monitoring compared to treatment based on intracranial pressure (ICP) monitoring alone.
Award Number	U01NS099046 (Barsan)
Funding Period	07/01/18-06/30/24
Amount	$8,525,394
Time Commitment	1%
Agency Contact	Maria Mendoza-Puccini, 301-496-9135, maria.mendoza.puccini@nih.gov
Overlap	None

EMS-TruShoC’ – A Prospective Trial of Low-Dose, High-Frequency, On-Site Training to Improve Trauma Field Care in Austere Settings
Funding Agency	Defense Health Agency (J9, Research and Development Directorate); US Department of the Air Force (59th Medical Wing)
Role	Co-Investigator
Description / Aims	The goal of this project is to implement EMS-TruShoC in an austere setting and assess the resultant educational and clinical outcomes. These prehospital trauma resuscitation concepts will inform future efforts to translate into USSOF and conventional military prehospital training and sustaining knowledge.
Award Number	FA8650-18-2-6934 (Mould-Millman/Schauer)
Funding Period	07/30/18-07/29/21
Amount	$155,000
Time Commitment	1.75%
Agency Contact	Clifford Johnson, 937-713-9922, Clifford.johnson.4@us.af.mil
Overlap	None

Precision Medicine Approach to Vitamin D3 Administration in Critical Illness
Funding Agency	Funding Agency: National Heart, Lung, and Blood Institute (NHLBI)
Role	SubAward PI/Co-Investigator
Description / Aims	The goal of this study is using a precision medicine approach to investigate the clinical, genetic, and biochemical factors that determine response to vitamin D3 administration in critical illness.
Award Number	R01HL544166 (Leaf)
Funding Period	07/01/19-06/30/23
Amount	$457,978
Time Commitment	5%
Agency Contact	Lora Reineck, 301-435-0222, lora.reineck@nih.gov
Overlap	None

The Impact of Fluid Resuscitation on Glycocalyx Degradation in Septic Shock
Funding Agency	National Heart, Lung, and Blood Institute (NHLBI)
Role	Co-Investigator
Description / Aims	The goal of this project is to determine the mechanism of intravenous fluid resuscitation in glycocalyx degradation and adverse clinical outcomes in septic shock.
Award Number	R01HL149422 (Shapiro/Schmidt)
Funding Period	09/01/19-05/31/23
Amount	$11,000
Time Commitment	1%
Agency Contact	Lora Reineck, 301-435-0222, lora.reineck@nih.gov
Overlap	None

Establishing the Epidemiology and Outcomes of Combat-Relevant Prolonged Trauma Care: A Prospective Multicenter Prehospital Pilot Study in South Africa
Funding Agency	Department of Defense (USAMCMR)
Role	Co-Investigator
Description / Aims	The goal of this project is to assess the effect of prolonged durations of prehospital care, and key prehospital interventions, on morbidity and mortality of patients with combat-like injuries.
Award Number	BA190054 (Mould-Millman)
Funding Period	09/30/19-09/29/21
Amount	$490,079
Time Commitment	5%
Agency Contact	Jennifer Shankle, 301-619-2193, Jennifer.e.shankle.civ@mail.mil
Overlap	None

Multicenter Implementation Trial of Targeted Normoxia Strategy to Define Oxygen Requirements for Major Burn Patients: An Approach to Reduce Warfighter Morbidity, Deployed Logistical Burden of Oxygen, and Readiness Costs
Funding Agency	Department of Defense/ Medical Technology Enterprise Consortium (MTEC)
Role	Principal Investigator
Description / Aims	The goal of this study is to determine the feasibility, safety, and effectiveness of the targeted normoxia approach to conserve oxygen and improve clinical outcomes in major burn patients.
Award Number	MTEC-19-08-MuLTI-0043
Funding Period	01/30/20-01/29/23
Amount	$2,492,920
Time Commitment	10%
Agency Contact	Jenifer Ojeda, 301-619-0193, Jenifer.f.ojeda.civ@mail.mil
Overlap	None

Multicenter Implementation Trial of Targeted Normoxia Strategy to Define Oxygen Requirements for Combat Casualty Care
Funding Agency	Department of Defense (Joint Warfighter Medical Research Program)
Role	Principal Investigator
Description / Aims	The goal of this study is to determine the feasibility, safety, and effectiveness of the targeted normoxia approach to conserve oxygen and improve clinical outcomes in critically injured patients
Award Number	JW190515 (Ginde)
Funding Period	03/01/20-02/28/23
Amount	$3,796,345
Time Commitment	10%
Agency Contact	Sandy Snyder, 301-619-7047, sandy.j.snyder.civ@mail.mil
Overlap	None

Innovative Methods to Evaluate the Role of Influenza Vaccines in Attenuating Severe Disease in Adults
Funding Agency	Centers for Disease Control and Prevention (CDC)
Role	Co-Investigator/Site PI
Description / Aims	The goal of this study is to understand the role of influenza infection and other viral infections including COVID-19 in critical illness, define and sub-phenotype severe influenza disease, and quantify the effectiveness of influenza vaccines for mitigating influenza-associated morbidity and mortality.
Award Number	75D30120R67837 (Self)
Funding Period	03/27/20-06/30/21
Amount	$200,000 (est, depending on enrollment)
Time Commitment	1%
Agency Contact	Vallerie Redd, 770-488-2845
Overlap	None

Outcomes Related to COVID-19 treated with Hydroxychloroquine among In-patients with symptomatic Disease (ORCHID)
Funding Agency	National Heart, Lung, and Blood Institute (NHLBI)
Role	Co-Investigator/Site PI
Description / Aims	This project will be a randomized controlled trial to compare the safety and efficacy of hydroxychloroquine versus placebo in hospitalized patients with laboratory-confirmed COVID-19
Award Number	5U01HL123009-06S1 (Thompson)
Funding Period	04/15/20-04/14/21
Amount	$3,662,154
Time Commitment	1%
Agency Contact	Lora Reineck, 301-435-0222, lora.reineck@nih.gov
Overlap	None

CORAL: PETAL COVID-19 Observational Study
Funding Agency	National Heart, Lung, and Blood Institute (NHLBI)
Role	Site PI
Description / Aims	Observational study of hospitalized patients with COVID-19 using both retrospective and prospective methods.
Award Number	5U01HL123009-06S2 (Thompson)
Funding Period	04/24/20-04/23/21
Amount	$5,278,145
Time Commitment	1%
Agency Contact	Lora Reineck, 301-435-0222, lora.reineck@nih.gov
Overlap	None

Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO)
Funding Agency	National Heart, Lung, and Blood Institute (NHLBI)
Role	Site PI
Description / Aims	The goal of this study to determine the efficacy and safety of a single dose of convalescent plasma (CP) for preventing the progression from mild to severe COVID-19 illness.
Award Number	1OT2HL156812 (Korley)
Funding Period	06/01/20-05/31/21
Amount	SubAward $36,000 (est, depending on enrollment)
Time Commitment	1%
Agency Contact	Maria Mendoza-Puccini, 301-496-9135, maria.mendoza.puccini@nih.gov
Overlap	None

Internationally Coordinating Center for ACTIV-3 Trial Initiative
Funding Agency	National Heart, Lung, and Blood Institute (NHLBI)
Role	Co-Investigator/Site PI
Description / Aims	The goal of this project is to design and oversee the trial, drafting, and revising standard operating procedure documents and FAQs, interactions with DSMB, NHLBI, International Coordinating Center (ICC), running and attending meetings, and serving as an on-call PETAL Investigator for the ACTIV-3 COVID-19 protocol.
Award Number	1OT2HL156812 (Thomas)
Funding Period	07/15/20-07/14/21
Amount	$200,000 (est, depending on enrollment)
Time Commitment	10%
Agency Contact	Lora Reineck, 301-435-0222, lora.reineck@nih.gov
Overlap	None

An end-user assessment of the novel iView video laryngoscope
Funding Agency	USAF/AFMC
Role	Site co-investigator
Description / Aims	The goal of this study to is to compare the use of the novel iView laryngoscope to traditional video laryngoscopy during acute airway management.
Award Number	FA8650-20-2-6227 (Schauer)
Funding Period	10/01/20-09/30/21
Amount	$242,000
Time Commitment	2%
Agency Contact	Vanessa Vazquez, 937-938-3192, Vanessa.vazquez.5@us.af.mil
Overlap	None

Passive Immunity for Our Nation (PassItOn)
Funding Agency	National Center for Advancing Translational Sciences (NCATS)
Role	Site PI
Description / Aims	The goal of this phase III trial is to compare the efficacy and safety of convalescent plasma versus placebo among adults hospitalized with COVID-19.
Award Number	3UL1TR002243-04S3 (Bernard)
Funding Period	08/18/20-08/31/21
Amount	$738,000 (est, depending on enrollment)
Time Commitment	1%
Agency Contact	Rashmi Gopal-Srivastava, gopalr@mail.nih.gov
Overlap	None

Epidemiology and Outcomes of Combat-Relevant Prolonged Trauma Care: A Prospective Multicenter Prehospital Study in South Africa
Funding Agency	Department of Defense/U.S. Army
Role	Co-PI
Description / Aims	The goal of this project is to conduct a multicenter epidemiologic study that assesses the effect of prolonged durations of prehospital care, and key prehospital interventions, on morbidity and mortality of civilian patients with combat-like injuries.
Award Number	BA190049
Funding Period	09/30/2020 – 09/29/2024
Amount	$5,415,483
Time Commitment	3%
Agency Contact	Jennifer Shankle, 301-619-2193, Jennifer.e.shankle.civ@mail.mil
Overlap	None

Adult Inpatient/Outpatient VE Case-Control Study
Funding Agency	Centers for Disease Control and Prevention (CDC)
Role	Co-Investigator/Site PI
Description / Aims	The goal of this study is to evaluate vaccine effectiveness of SARS-CoV-2 vaccination against symptomatic, medically attended SARS-CoV-2 infection by vaccine product.
Award Number	75D30121F00002 (Self)
Funding Period	02/05/21-02/14/22
Amount	$12,960,835
Time Commitment	1%
Agency Contact
Overlap

Implementation and Effectiveness of Monoclonal Antibodies to Treat High-Risk Outpatients with COVID-19
Funding Agency	National Center for Advancing Translational Sciences (NCATS)
Role	Co-Investigator
Description / Aims	The goal of this project is to develop, implement, and evaluate strategies to optimize equitable nMAb access in Colorado and determine the effectiveness and safety of nMAb treatment in high-risk COVID-19 outpatients.
Award Number	UL1 TR002535-03S3 (Sokol/Ginde)
Funding Period	3/15/2021-4/30/2022
Amount	$8,699,359
Time Commitment	15%
Agency Contact	Pablo Cure, 301-827-2014,pablo.cure@nih.gov
Overlap	None

Trial of Early Antiviral Therapies during Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19 to Reduce the Burden of Illness for U.S. Service Members
Funding Agency	FY20 BA 6.4 CARES Act Research and Development (RDT&E)
Role	Civilian PI
Description / Aims	The goal of this phase III trial is to test the efficacy and safety of the antiviral agent lopinavir/ritonavir to prevent disease progression and improve recovery in outpatients with COVID-19.
Award Number	AC20COV08
Funding Period	4/1/21-3/31/22
Amount	$2,500,000
Time Commitment	10%
Agency Contact	Mr. Ed Chagoy (59MDW), 210-292-2761, edward.a.chagoy.civ@mail.mil
Overlap

Human IFN Beta-1a In Severe CoronavirUS (HIBISCUS)
Funding Agency	FY20 BA 6.4 CARES Act Research and Development (RDT&E)
Role	Civilian PI
Description / Aims	The goal of this phase III trial is to test the efficacy and safety of intravenous interferon beta-1a in the treatment of patients with severe hypoxemic respiratory failure/ARDS due to COVID-19
Award Number	AC20COV09
Funding Period	4/1/21-9/30/22
Amount	$6,100,000
Time Commitment	10%
Agency Contact	Mr. Ed Chagoy (59MDW), 210-292-2761, edward.a.chagoy.civ@mail.mil
Overlap

Re-evaluation of Systemic Early neuromuscular blockade (ROSE)
Funding Agency	NHLBI/Massachusetts General Hospital Prevention and Early Treatment of Acute Lung Injury Network
Role	Co-Site PI/Co-Investigator
Description / Aims	The goal of this phase III trial is to determine the efficacy and safety of neuromuscular blockade in reducing mortality of emergency department and intensive care unit patients with moderate-severe acute respiratory distress syndrome.
Award Number
Funding Period	11/01/2015-06/30/2018
Amount	$291,050
Time Commitment	1%
Agency Contact	Lora Reineck, 301-435-0222, lora.reineck@nih.gov
Overlap	None

Vitamin D to Improve Outcomes by Leveraging Early Treatment (VIOLET)
Funding Agency	NHLBI/Massachusetts General Hospital Prevention and Early Treatment of Acute Lung Injury Network
Role	Principal Investigator
Description / Aims	The goal of this phase III trial is to determine if early administration of vitamin D reduces 90-day mortality in critically ill, vitamin D deficient patients at high-risk for developing acute respiratory distress syndrome (ARDS). I lead the conduct of a 3,000 patient, 48-institution randomized controlled trial.
Award Number
Funding Period	05/01/2016-01/31/2019
Amount	$13,218,470
Time Commitment	10%
Agency Contact	Lora Reineck, 301-435-0222, lora.reineck@nih.gov
Overlap	None

Targeting Steroid Resistance During Acute Exacerbations of COPD with Respiratory Failure – The AECOPD Resistance Study
Funding Agency	NIH/Colorado Clinical and Translational Sciences Institute (CCTSI) Team Science Award (PI: Vandivier)
Role	Co-Investigator
Description / Aims	The goals of this study are to determine the mechanisms and clinical implications of steroid resistance in emergency department patients during acute exacerbation of chronic obstructive pulmonary disease with respiratory failure who require mechanical ventilation and ICU admission.
Award Number
Funding Period	07/01/2016-06/30/2018
Amount	$100,000
Time Commitment	1%
Agency Contact	Tim Lockie, 720-848-6660, tim.lockie@cuanschutz.edu
Overlap	None

Targeted Normoxia to Conserve Oxygen and Improve Clinical Outcomes in Combat-Injured Special Operations Forces
Funding Agency	Department of Defense/U.S. Special Operations Command
Role	PD/PI
Description / Aims	The goal of this application is to determine the feasibility, safety, and potential effectiveness of targeted normoxia as a strategy to conserve oxygen and improve clinical outcomes in critically ill trauma patients.
Award Number	W81XWH-17-C-0241
Funding Period	09/29/17-01/28/20
Amount	$274,272
Time Commitment	10%
Agency Contact	Douglas Simpson, douglas.simpson@socom.mil
Overlap	None

Vitamin D to Improve Outcomes by Leveraging Early Treatment: Long-term Brain Outcomes in Vitamin D Deficient Patients (VIOLET BUD)
Funding Agency	Vanderbilt - National Heart, Lung, and Blood Institute (NHLBI)
Role	SubAward PI/Co-Investigator
Description / Aims	The goal of this project is to determine the effect of vitamin D repletion on long-term cognitive outcomes in critically ill patients.
Award Number	R56HL141567 (Han)
Funding Period	09/05/18-08/31/19
Amount	$92,352
Time Commitment	10%
Agency Contact	Lora Reineck, 301-435-0222, lora.reineck@nih.gov
Overlap	None

Vitamin C, Thiamine, and Steroids in Sepsis (VICTAS)
Funding Agency	Johns Hopkins University -The Marcus Foundation, Inc
Role	SubAward PI
Description / Aims	The goal of this study is to test the efficacy of vitamin C, thiamine, and steroids in reducing in-hospital mortality in critically ill patients with sepsis.
Award Number	#2393 (Rothman)
Funding Period	10/01/18-12/31/19
Amount	$219,394
Time Commitment	2%
Agency Contact	Amanda Bistran-Hall, 410-361-7999, abistra1@jhmi.edu
Overlap	None

Influenza Vaccine Effectiveness for Preventing Laboratory-Confirmed Severe Influenza-Associated Illness in US Adults
Funding Agency	Centers for Disease Control and Prevention (CDC)
Role	SubAward PI/Co-Investigator
Description / Aims	The goal of this study is to understand the role of influenza infection in critical illness and the effectiveness of influenza vaccines for mitigating influenza-associated morbidity and mortality.
Award Number	75D30119C05670 (Self)
Funding Period	07/10/19-07/09/20
Amount	$82,371
Time Commitment	1%
Agency Contact	Vallerie Redd, 770-488-2845
Overlap	None

Randomized Trial of Fresh Frozen Plasma Versus Albumin in Acute Burn Resuscitation
Funding Agency	Department of Defense/Military Burn Research Program
Role	Co-Investigator
Description / Aims	The goal of this study is to compare the safety and efficacy of fresh frozen plasma vs albumin for acute resuscitation of burn shock.
Award Number	MB200032 (Wiktor)
Funding Period	6/1/21-5/31/24
Amount	$1,495,647
Time Commitment	5%
Agency Contact	Eva Lai, eva.lai.ctr@mail.milrlap
Overlap	None

ACTIV-3/TICO

ACTIV-4 Host Tissue/NECTAR

Airway Research

BOOST

CLOVERS

DEVICE

HIBISCUS

ICECAP

iView

IVY 4 Network

Influenza Vaccine Effectiveness in the Critically Ill Network

Influenza Vaccine Effectiveness for Preventing Laboratory-Confirmed Severe Influenza-Associated Illness in US Adults
HCW Surveillance – COVID-19 Surveillance in Healthcare Workers and ICU Patients: Observational Studies

mAb Colorado

PETAL Network

Prevention and Early Treatment of Acute Lung Injury Network, funded by NHLBI. The goal of this application is to participate in the selection and conduct of clinical trials for the prevention and early treatment of acute lung injury across a network of 12 clinical centers. Our clinical center includes two academic and four community hospitals in the greater Denver area and a robust infrastructure for recruitment of critically ill emergency department and intensive care unit patients into clinical trials.

CLOVERS – Crystalloid Liberal Or Vasopressors Early Resuscitation in Sepsis
CORAL – COVID-19 Observational Study
ORCHID – Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-Patients with Symptomatic Disease
VIOLET BUD - Vitamin D to improve outcomes by Leveraging early treatment Long-term brain outcomes in vitamin D Deficient Patients

PREOXI

SAVE-O2

SAVE-O2 Trauma - Strategy to Avoid Excessive Oxygenation in Critically Injured Trauma Patients
SAVE-O2 Burn - Strategy to Avoid Excessive Oxygenation in Major Burn Patients

SEPSIGN

SIREN Network

BOOST-3 (Primary Study Coordinator) - Brain Oxygen Optimization in Severe Traumatic Brain Injury – Phase 3 (BOOST-3). The goal of this study to determine if there is evidence of clinical efficacy of a treatment protocol based on brain tissue oxygenation (PbtO2) monitoring compared to treatment based on intracranial pressure (ICP) monitoring alone.
ICECAP

TREAT NOW

Trial of Early Antiviral Therapies during Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19

High-Dose Vitamin D3 for Critically Ill Vitamin D-Deficient Patients. Reply.

Ginde AA, Talmor D; VIOLET Investigators and members of the National Heart, Lung, and Blood Institute PETAL Clinical Trials Network.

N Engl J Med. 2020 Apr 23;382(17):1670-1671. doi: 10.1056/NEJMc2000993. No abstract available.

PMID: 32320585

Early High-Dose Vitamin D₃ for Critically Ill, Vitamin D-Deficient Patients.

National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Ginde AA, Brower RG, Caterino JM, Finck L, Banner-Goodspeed VM, Grissom CK, Hayden D, Hough CL, Hyzy RC, Khan A, Levitt JE, Park PK, Ringwood N, Rivers EP, Self WH, Shapiro NI, Thompson BT, Yealy DM, Talmor D.

N Engl J Med. 2019 Dec 26;381(26):2529-2540. doi: 10.1056/NEJMoa1911124. Epub 2019 Dec 11.

PMID: 31826336

Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome.

National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Moss M, Huang DT, Brower RG, Ferguson ND, Ginde AA, Gong MN, Grissom CK, Gundel S, Hayden D, Hite RD, Hou PC, Hough CL, Iwashyna TJ, Khan A, Liu KD, Talmor D, Thompson BT, Ulysse CA, Yealy DM, Angus DC.

N Engl J Med. 2019 May 23;380(21):1997-2008. doi: 10.1056/NEJMoa1901686. Epub 2019 May 19.

PMID: 31112383

Liberal Versus Restrictive Intravenous Fluid Therapy for Early Septic Shock: Rationale for a Randomized Trial.

Self WH, Semler MW, Bellomo R, Brown SM, deBoisblanc BP, Exline MC, Ginde AA, Grissom CK, Janz DR, Jones AE, Liu KD, Macdonald SPJ, Miller CD, Park PK, Reineck LA, Rice TW, Steingrub JS, Talmor D, Yealy DM, Douglas IS, Shapiro NI; CLOVERS Protocol Committee and NHLBI Prevention and Early Treatment of Acute Lung Injury (PETAL) Network Investigators.

Ann Emerg Med. 2018 Oct;72(4):457-466. doi: 10.1016/j.annemergmed.2018.03.039. Epub 2018 May 10.

PMID: 29753517

Systematic review of oxygenation and clinical outcomes to inform oxygen targets in critically ill trauma patients.
Douin DJ, Schauer SG, Anderson EL, Jones J, DeSanto K, Cunningham CW, Bebarta VS, Ginde AA. J Trauma Acute Care Surg. 2019 Oct;87(4):961-977. doi: 10.1097/TA.0000000000002392.PMID: 31162333

A single-site pilot implementation of a novel trauma training program for prehospital providers in a resource-limited setting.
Mould-Millman NK, Dixon J, Lamp A, de Vries S, Beaty B, Finck L, Colborn K, Moodley K, Skenadore A, Glasgow RE, Havranek EP, Bebarta VS, Ginde AA. Pilot Feasibility Stud. 2019 Dec 5;5:143. doi: 10.1186/s40814-019-0536-0. eCollection 2019.PMID: 31844551

Treating Decompression Sickness: Military Flight Simulation Site-Community Hospital Partnership.

Rhodes WC, Hertner G, Price R, Finck L, Temmer C, Cushing T, Flarity K.

Mil Med. 2017 Jul;182(7):e1718-e1721. doi: 10.7205/MILMED-D-16-00386.

PMID: 28810963

Community Implementation of a Prehospital Spinal Immobilization Guideline.

Jones Rhodes W, Steinbruner D, Finck L, Flarity K.

Prehosp Emerg Care. 2016 Nov-Dec;20(6):792-797. Epub 2016 Jul 13.

PMID: 27410996

NIH
EMF
DoD

Our Team

Picture of Adit Ginde

Adit Ginde, MD, MPH
Principal Investigator

Picture of Erin Anderson

Erin Anderson, RN
Senior Professional Research Assistant

Picture of Jill Bastman

Jill Bastman, BSN, RN

Picture of Jessica Cwik

Jessica Cwik, BA

Picture of David Douin

David Douin, MD

Picture of David Huynh

David Huynh, BA

Picture of Conner Jackson

Conner Jackson, MS

Picture of Amanda Martinez

Amanda Martinez, MPH

Picture of Flora Martinez

Flora Martinez, MPH, RN

Picture of Jennifer Peers

Jennifer Peers, BSN, RN
Professional Research Assistant

Picture of John Rice

John Rice, PhD

Picture of Cori Withers

Cori Withers, BS

In the News

Dr. Ginde Describes how Monoclonal Antibody Treatment can Protect High Risk COVID Patients

Aug 31, 2021

Dr. Ginde appears on NBC's Nightly News to discuss how Monoclonal Antibody Treatment can Protect High Risk COVID Patients, and how UC Health is using the treatment to save lives.

Watch the video at NBC News >>>

Emergency Medicine (SOM)

CU Anschutz

Leprino Building

12401 East 17th Avenue

7th Floor

Aurora, CO 80045

720-848-6777

Tools & Resources

CU Campuses

CU Anschutz Medical Campus

Department of Emergency Medicine

School of Medicine

ATLAS – Airway, Trauma, Lung injury, and Sepsis Research